Aviron Announces $8 Million Financing - 500 Beiträge pro Seite

[korkut]

Friday May 12, 6:36 pm Eastern Time


MOUNTAIN VIEW, Calif., May 12 /PRNewswire/ -- Aviron (Nasdaq: AVIR - news) today announced that it has sold 348,983 shares of its common stock, registered under its Registration Statement on Form S-3 (No. 333-87185), to Acqua Wellington Asset Management LLC for an aggregate price of $8,000,000, or $22.92 per share. The company did not pay any fees or other compensation in connection with this transaction.

Net proceeds from the sale will be used to fund operating costs, capital expenditures and working capital needs, which may include costs of FluMist(TM) regulatory filings and the manufacturing and commercialization of FluMist(TM) in its current formulation; development of a second-generation formulation of FluMist(TM); research and development of other pipeline products; development of the infrastructure necessary to support these activities; and other general corporate purposes.

Aviron is a biopharmaceutical company based in Mountain View, California, focused on the prevention of disease through innovative vaccine technology.

Actual results may differ materially from the forward-looking statements contained in this release. Factors that could cause actual results to differ include, but are not limited to, failure to validate the manufacturing process, facilities or equipment for the company`s nasal influenza vaccine, and the assessment by regulatory agencies that the company`s future license applications for its nasal influenza vaccine are incomplete or inadequate to approve the product for marketing to one or more target populations. Additional information concerning factors that could cause such a difference is contained in Aviron`s SEC filings, including its S-3 Registration Statement and Annual Report on Form 10-K for the year ended December 31, 1999.

To receive an index and copies of recent press releases, call Aviron`s News-On-Call toll-free fax service, 800-758-5804, extension 114000. Additional information about the company can be found at http://www.aviron.com .

SOURCE: Aviron


Thursday May 11, 9:05 pm Eastern Time

Aviron Elects Mendelson to Board of Directors
MOUNTAIN VIEW, Calif., May 11 /PRNewswire/ -- Aviron (Nasdaq: AVIR - news) today announced that Alan C. Mendelson has been elected to the company`s board of directors, effective immediately.

Mr. Mendelson is a senior partner in the Menlo Park office of Latham & Watkins, a major global law firm. In addition to serving as Aviron`s corporate secretary since 1992, Mr. Mendelson also serves on the board of directors of Axys Pharmaceuticals Inc., iScribe Inc., Isis Pharmaceuticals Inc. and US SEARCH.com Inc. Twice, Mr. Mendelson has been recognized as one of America`s 100 most influential lawyers by the National Law Journal. Mr. Mendelson holds a bachelor`s degree from the University of California at Berkeley and a J.D. from the Harvard Law School.

``Alan`s knowledge of the biotechnology industry, his legal expertise and sound business judgment provide additional strength to Aviron`s board,`` said C. Boyd Clarke, Aviron president and chief executive officer.

Mr. Mendelson replaces Jane E. Shaw, Ph.D. on the board of directors. Charlene Friedman, Aviron vice president and general counsel, is the new corporate secretary.



Immerhin legte der Kurs in NY um 10% zu.

Gruß Korkut

[Hänsmän]

Du bist ja nur ein kleine billiger pusher, der keine Ahnung hat was wirklich abgeht... Hallo Kork! Schöner Text